Although highly effective, warfarin use is complicated by its unpredictable narrow
therapeutic window, genetic heterogeneity in pharmacokinetic response, numerous food …

Non-vitamin K antagonist oral anticoagulants (NOACs) have a favorable benefit-risk profile
compared with vitamin K antagonists. However, the lack of specific reversal agents has …

Anticoagulants are the mainstay of therapy for thromboembolic diseases. In addition to the
more traditional agents, new oral anticoagulants, including dabigatran etexilate …

The direct acting oral anticoagulants (DOAC s), including dabigatran, rivaroxaban,
apixaban, and edoxaban, have favorable pharmacokinetic and pharmacodynamic …

With the advent of new oral anticoagulants a thorough assessment and evaluation of
benefits weighed against potential risks must be conducted. In a practical sense, what will …

Oral anticoagulants are used to prevent and treat a wide range of thromboembolic diseases.
Currently available oral anticoagulants include the vitamin K antagonists (VKAs), such as …

Novel oral anticoagulants (NOAC) provide an effective and, in some cases, superior
alternative to traditional, oral vitamin K antagonists such as warfarin. These drugs differ in …

Oral anticoagulation therapy is transforming with the advent of the target specific oral
anticoagulants, particularly, the direct thrombin inhibitors and factor Xa inhibitors. These …

The new oral anticoagulants dabigatran etexilate (Pradaxa), rivaroxaban (Xarelto), and
apixaban (Eliquis) have predictable pharmacokinetic and pharmacodynamic profiles and …

The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for many
indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban …